Health Care & Life Sciences » Biotechnology | Hemispherx Biopharma Inc.

Hemispherx Biopharma Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
150.00
197.00
133.00
92.00
437.00
Cost of Goods Sold (COGS) incl. D&A
1,234.00
1,251.00
1,598.00
2,277.00
1,183.00
Gross Income
1,084.00
1,054.00
1,465.00
2,185.00
746.00
SG&A Expense
15,907.00
17,599.00
14,970.00
11,485.00
10,663.00
EBIT
16,991.00
18,653.00
16,435.00
13,670.00
11,409.00
Unusual Expense
695.00
131.00
315.00
3,169.00
2,410.00
Non Operating Income/Expense
686.00
680.00
1,159.00
2,870.00
791.00
Interest Expense
16.00
11.00
3.00
-
139.00
Pretax Income
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
Consolidated Net Income
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
Net Income
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
Net Income After Extraordinaries
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
Net Income Available to Common
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
EPS (Basic)
1.16
1.11
0.72
0.34
0.29
Basic Shares Outstanding
13,943.80
15,691.00
19,679.30
21,818.20
28,676.10
EPS (Diluted)
1.16
1.11
0.77
0.34
0.29
Diluted Shares Outstanding
13,943.80
15,691.00
19,679.30
21,818.20
28,676.10
EBITDA
16,300.00
17,957.00
15,460.00
12,501.00
10,405.00
Non-Operating Interest Income
791.00
665.00
364.00
129.00
88.00

About Hemispherx Biopharma

View Profile
Address
2117 South West Highway 484
Ocala Florida 32801
United States
Employees -
Website http://www.hemispherx.net
Updated 09/14/2018
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.